logo-loader
viewCytoDyn Inc.

FDA accepted CytoDyn’s request and plan to submit BLA on rolling basis

CytoDyn Inc. (OTCQB:CYDY) President and CEO Dr. Nader Pourhassan joined Steve Darling from Proactive Investors Vancouver on Skype to talk about encouraging news that the FDA will allow CytoDyn to submit on a rolling basis its planned Biologics License Application for  Leronlimab. This is a humanized IgG4 mAb that is subcutaneously injected to block HIV-1 from entering and infecting immune cells.

Pourhassan told Proactive how rare this is for a company their size and when the first submissions will be made. 

Quick facts: CytoDyn Inc.

Price: 5.07 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $2.63 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn addresses negative claims made by healthcare publication STAT on its...

CytoDyn (OTCQB:CYDY) CEO Nader Pourhassan spoke to Proactive, addressing negative claims made by healthcare publication STAT on its coronavirus study. Pourhassan says the company has released what he says are positive results from its coronavirus treatment clinical study, and explains why he...

4 days, 7 hours ago

2 min read